Resistin - the link between adipose tissue dysfunction and insulin resistance in patients with obstructive sleep apnea

Journal of Diabetes & Metabolic Disorders

Vanio Ivanov Mitev¹  Adelina Dimitrova Cakova¹  Sylvia Rumenova Ruseva¹  Tsanko Lilianov Mondeshki²  Daniela Stoichkova Petrova²  Ognian Borisov Georgiev²  Radostina Vlaeva Cherneva² 

[1] Department of Medical Chemistry and Biochemistry, Laboratory of Synthesis and Analysis of Bioactive Substances, Medical University, Sofia, Zdrave 2str, Sofia 1431, Bulgaria;Department of Internal Medicine, Division of Pulmonary Medicine, Medical University, Sofia, Georgi Sofiiski 1str, Sofia 1431, Bulgaria

关键词: Impaired glucose tolerance;    Normal glucose metabolism;    Diabetes;    OSA;    Insulin resistance;    Resistin;   

Others  :  807134
DOI  :  10.1186/2251-6581-12-5

 received in 2012-09-21, accepted in 2013-01-07,  发布年份 2013

【 摘 要 】

Background

Resistin is an adipocytokine, associated with obesity and inflammation. Its exact role in insulin resistance and diabetes in the general population is still controversial. The relation between resistin plasma levels, insulin resistance and risk of impaired glucose metabolism in OSA patients has not been investigated.

Materials and methods

Plasma levels of resistin were measured in 67 patients with OSA and impaired glucose metabolism. 34,7% (23/67) had diabetes; 40% (27/67) patients had impаired glucose tolerance(IGT); 25,3%(17/67) had normal glucose metabolism (NGM). The association between resistin, BMI, obesity, markers of insulin resistance, oxidative stress and sleep study characteristics was analysed. The different groups of patients were compared in regards to glucometabolic parameters and biomarkers of oxidative stress – isoprostanes and insulin resistance – free fatty acids (FFA).

Results

Plasma levels of resistin were higher in patients with diabetes (6,12 ±5,93ng/ml), compared to those with IGT (3,85±2,81ng/ml, p-0,021) and NGM (3,77±3,23, p-0,043). Resistin did not differ between patients with IGT and NGM (p-0,954). In OSA patients with BMI>40 resistin plasma levels correlated neither to the clinical parameters (BMI, IRI, HOMA-I, HbA1C, AHI, desaturation index), nor to the biomarkers of oxidative stress and insulin resistance. Free fatty acids (0,232>0,177mmol/l, p-0,037) were higher in diabetics in comparison to NGM.

Conclusions

Plasma resistin levels in OSA patients with BMI>40 are independent of insulin resistance and are not associated with the parameters, characterising the oxidative stress or severity of OSA. Resistin could be used in a multiple panel of clinical and biomarkers to discern patients with diabetes from those with IGT; in OSA patients with BMI >40 resistin together with HbA1C could discern patients with diabetes from those with NGM. In OSA patients with BMI >40 FFA and HbA1C are useful clinical markers in assessing the risk of dysglycaemia among patients with normal and IGT.

【 授权许可】

   
2013 Cherneva et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hatipoglu U, Rubinstein I: Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003, 70:665-671.
• [2]Tanriverdi H, Evrengul H, Kara CO, Kuru O, Tanriverdi S, Ozkurt S, Kaftan A, Kilic M: Aortic stiffness, flow-mediated dilatation and carotid intima-media thickness in obstructive sleep apnea: non-invasive indicators of atherosclerosis. Respiration 2006, 73:741-750.
• [3]Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, Okada S, Ohta S, Naito H, Adachi M: Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005, 172:625-630.
• [4]Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS: Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002, 165:670-676.
• [5]Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE: Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004, 160:521-530.
• [6]McArdle N, Hillman D, Beilin L, Watts G: Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007, 175:190-195.
• [7]Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004, 25:735-741.
• [8]Lam JC, Lam B, Lam CL, Fong D, Wang JK, Tse HF, Lam KS, Ip MS: Obstructive sleep apnea and the metabolic syndrome in community- based Chinese adults in Hong Kong. Respir Med 2006, 100:980-987.
• [9]Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88:1730-1736.
• [10]Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA: High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53:1279-1284.
• [11]Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
• [12]McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S: Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002, 87:2407-2411.
• [13]McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S: Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88:6098-6106.
• [14]Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
• [15]Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ: Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:182-188.
• [16]Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004, 2(1):161-168.
• [17]Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
• [18]Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
• [19]Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
• [20]Blaak EE: Fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc Nutr Soc 2003, 62:753-760.
• [21]Sarafidis PA, Bakris GL: Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/ insulin resistance? J Hum Hypertens 2007, 21:12-19.
• [22]Nourooz-Zadeh J: Key issues in F2-isoprostane analysis. Biochem Soc Trans 2008, 36:1060-1065.
• [23]Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ: А series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990, 87:9383-9387.
• [24]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and_ -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [25]Committee E: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1189.
• [26]Phillips LK, Prins JB: The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008, 2008(10):156-164.
• [27]Pittas AG, Joseph NA, Greenberg AS: Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004, 89:447-452.
• [28]Beltowski J: Adiponectin and resistin—new hormones of white adipose tissue. Med Sci Monit. 2003, 9(2):55-61.
• [29]Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
• [30]Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA: Regulation of fasted blood glucose by resistin. Science 2004, 303:1195-1198.
• [31]Rajala MW, Obici S, Scherer PE, Rossetti L: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003, 111:225-230.
• [32]Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA: Abnormal Glucose Homeostasis due to Chronic Hyperresistinemia. Diabetes 2004, 53:1937-1941.
• [33]Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR: Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848.
• [34]Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
• [35]Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA: High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 2004(53):1279-1284.
• [36]Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino RB Sr, Wilson PW, Meigs JB: Associations of adiponectin, resistin, and tumor necrosis factor-_ with insulin resistance. J Clin Endocrinol Metab 2008, 93:3165-3172.
• [37]Yamamoto Y, Fujiuchi S, Hiramatsu M, Nishigaki Y, Takeda A, Fujita Y, Yamazaki Y: Resistin Is Closely Related to Systemic Inflammation in Obstructive Sleep Apnea. Respiration 2008, 76:377-385.
• [38]Wysocka E, Cofta S, Dziegielewska S, Gozdzik J, Torlinski L, Batura-Gabryel H: Adipocytokines in sleep apnea syndrome. Eur J Med Res. 2009, 14(4):255-258. BioMed Central Full Text
• [39]Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
• [40]Patel C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR_ activators. Biochem Biophys Res Commun 2003, 300:427-476.
• [41]Li M, He XG, Qu SH, Zhan HM, Yang YB, Xu X, Si YF: Plasma resistin level in obstructive sleep apnea hypopnea syndrome. Zhonghua Yi Xue Za Zhi. 2008, 88(34):2399-2402.
• [42]Wasilewska J, Kaczmarski M, Sawicka-Zukowska M, Serum resistin level in pediatric obstructive sleep apnea. Thematic Poster Session: Paediatric respiratory epidemiology I: primary ciliary dyskinesia, sleep-disordered breathing, exercise-induced symptoms and rare diseases. 2008. Tuesday, 07 October 2008
• [43]Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA: High plasma resistin level is associated with enhanced highly sensitive C reactive protein and leukocytes. J Clin Endocrinol Metab 2006, 91:2755-2760.